Navigation Links
S*BIO's Novel JAK2 Inhibitor Pacritinib (SB1518) Effectively Reduces Splenomegaly in Myelofibrosis (MF) Patients With Minimal Impact on Existing Cytopenias Providing Important Therapeutic Niche In Treatment of MF
Date:12/12/2011

SINGAPORE, Dec. 12, 2011 /PRNewswire/ -- S*BIO Pte Ltd today announced that results from a Phase 2 study demonstrated that its JAK2 inhibitor pacritinib (SB1518) effectively reduced splenomegaly in myelofibrosis (MF) patients, with minimal impact on existing cytopenias providing an important therapeutic niche in the treatment of MF. Results were presented at the 53rd ASH Annual Meeting and Exposition in San Diego.

"Pacritinib is an active drug for the treatment of splenomegaly in patients with primary myelofibrosis, post-polycythemia vera-myelofibrosis and post-essential thrombocythemia-myelofibrosis regardless of baseline thrombocytopenia," said Rami S. Komrokji, M.D., principal author of the oral presentation. "The once daily dose of pacritinib was well tolerated with manageable gastrointestinal toxicity as the main side effect. The minimal impact on existing cytopenias in MF patients provides an important therapeutic outcome for pacritinib in the treatment of this patient population. The results support the rapid advancement of pacritinib into Phase 3 clinical trials to further support its safety and efficacy."

The primary endpoint of pacritinib's Phase 2 study was to assess the spleen response rate, defined as a >/=35% reduction in MRI-measured spleen volume between baseline and week 24. Thirty-four MF patients were enrolled in the study. The most common treatment-related adverse events were gastrointestinal, which were generally low grade and easily managed.  Pacritinib was equally well tolerated by patients with normal platelet counts and those with thrombocytopenia and anemia. Thirty patients (88%) showed reduction in palpable splenomegaly, 14 (41%) showed decreases of >/=50% and five (15%) achieved clinical resolution of splenomegaly. Eight patients (24%) had decreases in spleen volume by >/=35%.  Spleen response rates were equivalent among patients with low baseline platelet counts and those with normal baseline cou
'/>"/>

SOURCE S*BIO Pte Ltd
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. University Hospitals Seidman Cancer Center Tests Novel Drug That Makes Brain Tumors Glow Hot Pink
2. Novelos Therapeutics Prices $5.9 Million Public Offering
3. MacroGenics and Servier Enter Development and Commercialization Agreement for Novel Anti-Cancer Drug
4. Unigenes Proprietary Peptelligence™ Platform Used to Commence Cara Therapeutics Phase 1 Clinical Trial of Oral Novel Peripherally-Acting Kappa Opioid Agonist
5. New Study Points to Novel Mechanism by Which Tumors Escape Recognition by the Immune System
6. Cara Therapeutics Initiates Phase I Study with Oral Formulation of Novel Peripherally-Acting Kappa Opioid Agonist
7. Niiki Pharma Reports on Synergistic Activity of Novel Anti-Cancer Agent NKP-1339 with Other Anti-Cancer Agents
8. CureFAKtor Pharmaceuticals Demonstrates Novel Focal Adhesion Kinase (FAK) Inhibitor C4 Analogs Inhibited Pancreatic Cancer Tumor Growth as Single Agents
9. Childrens Hospital Boston and Pfizer Enter Into Novel Collaborative Research Agreement for Muscular Dystrophy Therapeutics
10. ChemoCentryx Reports Clinical Efficacy for CCX354, a Novel CCR1 Inhibitor in a Phase II Study in Patients with Rheumatoid Arthritis
11. Metabolex to Present Data on Arhalofenate, a Potential Novel Treatment for Gout, at the 2011 ACR/ARHP Annual Scientific Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/5/2015)... May 5, 2015  The preclinical contract research organization ... testing of drugs and safety testing of medical devices, ... of Preclinical Studies, presented at this week,s annual meeting ... (ARVO) in Denver, CO. The ... of a Novel, Cross-Linked, Bio-Absorbable Carboxymethyl Hyaluronic Acid (CMHA) ...
(Date:5/5/2015)... and NIJMEGEN, the Netherlands ... medical device company developing lower esophageal sphincter (LES) ... long-term, 3-year, positive safety and efficacy results. The ... of both heartburn and regurgitation and the "gold-standard" ... test) with near-complete elimination of dependence on daily ...
(Date:5/5/2015)... and Markets ( http://www.researchandmarkets.com/research/9pthtm/home_healthcare ) has announced ... - Forecast to 2020" report to their offering. ... reach more than $300+ billion growing at a CAGR ... market is expected to grow at a faster rate ... gaining a tremendous attention over hospitals for the sophistication, ...
Breaking Medicine Technology:Dr. Glen Gum of Absorption Systems Presents at The Association for Research in Vision and Ophthalmology (ARVO) Meeting 2Dr. Glen Gum of Absorption Systems Presents at The Association for Research in Vision and Ophthalmology (ARVO) Meeting 3Excellent three year results of EndoStim therapy for severe reflux disease presented at the SAGES Annual Meeting in Nashville. 2Excellent three year results of EndoStim therapy for severe reflux disease presented at the SAGES Annual Meeting in Nashville. 3Global Home Healthcare Global Market 2015 - Forecast to 2020 for the $300 Billion Market 2
... More Effective Monitor Than, Hemoglobin A1C of Exenatide, Sitagliptin, ... ... 7 GlycoMark, Inc. announced today,results from the ongoing ... a better reflection of glucose, particularly after-meal,glucose levels, than ...
... June 6 , - "ADVANCE Results go ... world,s largest ever study of diabetes treatments,show that ... and other drugs as required, protects patients against ... reduces,the risk of kidney disease by one-fifth. Presented ...
Cached Medicine Technology:DURABLE Clinical Trial Results Show GlycoMark is Key Test for Managing Patients with Diabetes 2DURABLE Clinical Trial Results Show GlycoMark is Key Test for Managing Patients with Diabetes 3The Largest Ever Study of Diabetes Shows Intensive Glucose Control Reduces Serious Complications 2
(Date:5/5/2015)... Private equity consultant and international research ... that its dental stem cell biobank project, Provia ... April, 2015 –and posted yet another exciting record. This ... and represents a significant 54% increase over last April ... is conducted via the Store-A-Tooth brand. The company has ...
(Date:5/5/2015)... 2015 NCPDP announced today that ... program establishes a three-year commitment of strategic support for ... Elite Partners. “AmerisourceBergen has supported our multi-stakeholder forum over ... “and this is a wonderful continuation and expansion of ... trace AmerisourceBergen back to our very first Board of ...
(Date:5/5/2015)... NY (PRWEB) May 05, 2015 Leveraging ... Clinic in Greece, an experienced team of fertility ... of infertility for patients around the globe. , “We’re ... VisitandCare.com. Greece unquestionably remains a global leader in reproductive ... and hard-working fertility specialists in the world who play ...
(Date:5/5/2015)... New York, New York (PRWEB) May 05, ... treatment lawsuits ( http://www.testosteronelawsuithub.com/ ) filed on ... cardiovascular complications due to their use of ... forward in the federal multidistrict litigation underway ... Illinois. According to court documents dated May ...
(Date:5/5/2015)... (PRWEB) May 05, 2015 Baptist Medical ... Commission on Cancer (CoC) of the American College of ... program must meet more than 30 Commission on Cancer ... a survey process, and maintain levels of excellence in ... When patients choose to seek care locally at a ...
Breaking Medicine News(10 mins):Health News:Grace Century’s Dental Stem Cell Biobank Project Announces Serial Record Enrollment Growth 2Health News:Grace Century’s Dental Stem Cell Biobank Project Announces Serial Record Enrollment Growth 3Health News:AmerisourceBergen Joins NCPDP Elite Partner Program 2Health News:AmerisourceBergen Joins NCPDP Elite Partner Program 3Health News:Maternity Health IVF Clinic in Greece Demonstrates Industry-Leading Fertility Technology 2Health News:Maternity Health IVF Clinic in Greece Demonstrates Industry-Leading Fertility Technology 3Health News:Federal Testosterone Lawsuit Defendants Recently Submitted Answers to Master Long Form Complaint 2Health News:Federal Testosterone Lawsuit Defendants Recently Submitted Answers to Master Long Form Complaint 3Health News:Federal Testosterone Lawsuit Defendants Recently Submitted Answers to Master Long Form Complaint 4Health News:Baptist Medical Center Jacksonville Receives National Cancer Reaccreditation 2Health News:Baptist Medical Center Jacksonville Receives National Cancer Reaccreditation 3Health News:Baptist Medical Center Jacksonville Receives National Cancer Reaccreditation 4
... ... ... ... ...
... ... ... , ... , , , , ...
... ... ... , ... , , ...
... 2010 winners of the Young Investigator Award. This ... individuals within 5 years of receiving doctoral degrees who ... Biology 2010 meeting in Anaheim in April 2010. ... by a committee on the basis of originality and importance ...
... ... of the Center for Quality Growth and Regional Development at Georgia Institute of Technology, ... Forum: Livability and Sustainable Communities – Taking Action for a Clean Energy Future. ... Atlanta, Ga. (PRWEB) ...
... ... ... ... ...
Cached Medicine News:Health News:FDA, FSIS, CDC Collaborate on Methods to Measure Success of Food Safety Programs 2Health News:FDA, FSIS, CDC Collaborate on Methods to Measure Success of Food Safety Programs 3Health News:FDA, FSIS, CDC Collaborate on Methods to Measure Success of Food Safety Programs 4Health News:FDA, FSIS, CDC Collaborate on Methods to Measure Success of Food Safety Programs 5Health News:FDA, FSIS, CDC Collaborate on Methods to Measure Success of Food Safety Programs 6Health News:Consumer Alert: Denture Cream Maker Warns Doctors of Product Dangers 2Health News:Consumer Alert: Denture Cream Maker Warns Doctors of Product Dangers 3Health News:Consumer Alert: Denture Cream Maker Warns Doctors of Product Dangers 4Health News:89 Women Celebrate Mardi Gras with Mammograms 2Health News:89 Women Celebrate Mardi Gras with Mammograms 3Health News:SEBM Young Investigator Awards for 2010 2Health News:Dr. Catherine Ross to Participate Today in White House Clean Energy Economy Forum 2Health News:Dr. Catherine Ross to Participate Today in White House Clean Energy Economy Forum 3Health News:Second Dose of Gene Therapy for Inherited Blindness Proves Safe in Animal Studies 2Health News:Second Dose of Gene Therapy for Inherited Blindness Proves Safe in Animal Studies 3Health News:Second Dose of Gene Therapy for Inherited Blindness Proves Safe in Animal Studies 4Health News:Second Dose of Gene Therapy for Inherited Blindness Proves Safe in Animal Studies 5Health News:Second Dose of Gene Therapy for Inherited Blindness Proves Safe in Animal Studies 6Health News:Second Dose of Gene Therapy for Inherited Blindness Proves Safe in Animal Studies 7
... MB Grade PRODUCT SPECIFICATIONS Form: Granular, free flowing powder ... 0.12 Gel Point (3%): less than or equal ... equal to 76C Gel Strength (3%): greater than or ... greater than or equal to 1000 gm/cm 2 ...
... chloride (Cl) ≤ 500 mg/kg sulfate (SO 4 ) ... Cd ≤ 5 mg/kg Co ≤ 5 mg/kg Cr ... 10 mg/kg K ≤ 50 mg/kg Mg ≤ 50 ... Ni ≤ 5 mg/kg Pb ≤ 5 mg/kg Zn ...
... Application: Forms strong flexible ... ( ID clarifier: mixture of ... 3:1 Solubility: water 10 mg/mL, ... grade: for molecular biology MP: ...
Inquire...
Medicine Products: